HLB Therapeutics Co., Ltd. (115450)

Overview

HLB Therapeutics Co., Ltd. is a pioneering biotech firm engaged in the research, development, and distribution of innovative pharmaceutical solutions, serving both the South Korean market and clients globally. The company exhibits a profound commitment to addressing a variety of healthcare challenges through its extensive research and development initiatives. Originally established in 2000 and known as G-treeBNT Co., Ltd., the entity underwent a strategic rebranding to HLB Therapeutics Co., Ltd. in December 2021. With its headquarters located in Seongnam, South Korea, HLB Therapeutics leverages cutting-edge biotechnology to forge breakthroughs in medical science, particularly focusing on treatments for ophthalmic diseases and brain tumors. Beyond its primary focus on pharmaceuticals, the company diversifies its portfolio through involvement in the wholesale of vaccines and the manufacture of crucial electrical and electronic components, including motors, pumps, and transformers, showcasing a versatile business model designed to address both healthcare needs and technological advancements.

Products and Services

• GBT-201 (Thymosin beta)

  GBT-201 stands as a hallmark of HLB Therapeutics' innovative approach to treating ophthalmic diseases, utilizing Thymosin beta. This drug candidate is under development to offer a novel therapeutic option for patients suffering from dry eye syndrome and neurotrophic keratopathy. By targeting these specific ophthalmic conditions, GBT-201 aims to improve the quality of life for individuals facing the discomfort and vision impairments associated with these diseases.

• OKN-007

  HLB Therapeutics is also advancing OKN-007, a promising therapeutic agent geared towards the treatment of glioblastoma, a highly aggressive and lethal brain tumor. This focus on developing a treatment for glioblastoma underscores the company's dedication to tackling some of the most challenging and underserved areas in oncology. If successful, OKN-007 could provide a much-needed lifeline to patients and families affected by glioblastoma, offering hope in the fight against this devastating disease.

• Vaccine Wholesale

  Aside from its pharmaceutical development endeavors, HLB Therapeutics engages in the wholesale of vaccines, reflecting its broader commitment to global health and disease prevention. By distributing vaccines, the company plays an integral role in protecting communities from infectious diseases, contributing to public health efforts and ensuring wider access to vital immunizations.

• Electrical and Electronic Components Manufacturing

  In addition to its primary focus on the healthcare sector, HLB Therapeutics has diversified its business operations to include the manufacturing of electrical and electronic components, such as motors, pumps, and transformers. This division underscores the company’s versatility and its strategy of leveraging its technological expertise beyond the pharmaceutical industry to meet a broader spectrum of consumer and industrial needs.